Eli Lilly (NYSE:LLY) may not have been the top-performing large-cap pharmaceutical stock, but its performance this year is nothing to sneeze at. As of this writing, LLY stock has soared nearly 35. ...

Eli Lilly & Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6% plunge — the worst session for the stock in nearly four years. The selloff followed the ...

Eli Lilly Downplays CVS Move to Drop Zepbound Coverage, Shares Plunge By Bhanvi Satija and Patrick Wingrove (Reuters) -Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's ...

Eli Lilly and Co.'s stock has jumped by more than 16% since the middle of July and by nearly 24% in 2018.Now it may face a huge reversal.The stock is poised to plunge 15% in the coming weeks ...

Eli Lilly faces challenges with slowing drug sales and a lawsuit against the HRSA. ... Pharmaceuticals stock Eli Lilly and Company ... a sharp plunge from the 71% QoQ increase seen in Q2 2024.

Eli Lilly had a bad quarter, with sales of GLP-1 drugs Mounjaro and Zepbound missing analyst estimates. The disappointment led to a plunge in Lilly’s shares early Wednesday that erased more than ...

On this episode of Stock Movers: - UnitedHealth (UNH) shares plunge after the company cut its annual forecast and reported its first earnings miss in over a decade. The company attributed the miss ...

An experimental Eli Lilly drug failed to significantly help Alzheimer’s disease patients in a closely watched clinical trial, dealing another blow to the pharmaceutical industry’s long quest ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still fell ...

(Reuters) -Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker ...